• Datavault AI signed a nonbinding letter of intent to acquire a 19.9% stake in DataMEDS on a fully diluted basis.
• Consideration would be an expanded technology license, with ownership of the underlying intellectual property retained by the licensor.
• DataMEDS would cover commercialization costs; the proposed arrangement offers potential royalty revenue to the licensor.
• Completion remains subject to due diligence, definitive agreements and customary closing conditions.
• CEO Nathaniel Bradley expects a fourth-quarter 2026 closing.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Datavault Ai Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 202610220800BIZWIRE_USPR_____20261022_BW362419) on October 22, 2026, and is solely responsible for the information contained therein.